Bionano Genomics, Inc. (Nasdaq: BNGO) today announced highlights from Day 3 of Bionano Symposium 2026, entitled OGM Making its Mark in Constitutional Genetic Disorders. Presentations highlighted how ...

Cytogenetics is the study of chromosomes, a vital tool to understanding how genetics play a role in the development and progression of certain diseases, as well as to predicting how a person will ...

Bionano Genomics, Inc. (Nasdaq: BNGO) today announced highlights from the fourth and final day of Symposium 2026. Day 4 featured updates from some of the most advanced and high-volume cytogenetics and ...

Bionano Symposium 2026 continues with Day 2: New Frontiers in Oncology and Bioprocessing Applications on February 24, 2026, from 7:00-10:00 AM PT. Attendees may also explore scientific posters ...

Thousands of chromosomal aberrations have been discovered in different types of cancer. But how do these various changes all hijack normal cellular processes to promote cancer? Although chromosomal ...

An important aim of recent cytogenetic developments has been to increase resolution. This has been achieved by advances that relate to the two elements of cytogenetic analysis, the target and the ...

It is crucial in the development of cell and gene therapies to understand the impact of the gene editing process on chromosomal structure. When cells are edited, differentiated, modified, or ...

New research shows that Optical Genome Mapping (OGM) detects abnormalities in chromosomes and DNA very quickly, effectively and accurately. Sometimes even better than all existing techniques together, ...

Panelists discuss how NCCN guidelines are expected to incorporate quadruplet-based regimens as reasonable treatment approaches for transplant-ineligible patients, while emphasizing the need for ...

Cytogenetics is a field of study that deals with chromosomes and related abnormalities. Chromosome analysis is also known as karyotyping and involves the pairing of homologous chromosomes.

NOTE. Comparison for complexity gives OR/HR between categories for patients with abnormal karyotype only; ORs for CR are calculated using logistic regression, and HRs for EFS, DFS, and OS are ...